Effect of peptide Vilon on the content of transforming growth factor-beta and permeability of microvessels during experimental chronic renal failure.
Gavrisheva. N A NA; Malinin. V V VV; Ses. T P TP; Kozlov. K L KL; Panchenko. A V AV; Titkov. A Yu AY
Key Findings
- Subcutaneous Vilon reduced serum TGF‑beta1 levels in rats with early chronic renal failure
- Vilon decreased permeability of mesenteric microvessels at 2 months after disease onset
- The effect was not observed at later time points (4‑6 months)
- The peptide appears to act as a homeostatic agent in early kidney disease
Practical Outcomes
- At this stage Vilon is only tested in animals, so there’s no safe dosage or protocol for people. Biohackers should view this as an early‑stage signal that more research is needed before trying it for kidney health or longevity.
Summary
In a rat study, giving the peptide Vilon under the skin lowered a harmful protein (TGF‑beta1) in the blood and made tiny gut blood vessels less leaky, but only when the rats were in the early stage of chronic kidney damage.
Abstract
We studied the effect of Vilon in rats 2, 4, and 6 months after the onset of chronic renal failure. Subcutaneous injection of Vilon significantly decreased serum concentration of transforming growth factor-beta(1) and permeability of mesenteric microvessels in rats 2 months after the onset of chronic renal failure. Our results indicate that the preparation produces a potent homeostatic effect in the early period of chronic renal failure.
Study Information
pubmed
2005
10.1007/s10517-005-0202-9
2
10